NCT00003837View on ClinicalTrials.gov

506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 1999

Study Completion Date

November 30, 2007

Conditions
LeukemiaLymphoma
Interventions
DRUG

nelarabine

Trial Locations (7)

20892

NCI - Pharmaceutical Management Branch, Bethesda

33612

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa

55905

Mayo Clinic Cancer Center, Rochester

91010-3000

City of Hope Comprehensive Cancer Center, Duarte

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

44106-5047

Case Comprehensive Cancer Center, Cleveland

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00003837 - 506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | Biotech Hunter | Biotech Hunter